Adrenal tumours secrete excessive hormones which adversely affect maternal and fetal health.
Adrenal tumours are managed with specific drugs or surgery, but it is not known how these affect the mother, the fetus or the neonate.
This study will investigate the current incidence of rare adrenal tumours including Phaeochromocytomas, those associated with Conn's Syndrome and Cushing's Syndrome. It will describe their current management and the associated outcomes for women and their infants and develop guidelines for their optimal management.
March 2011-February 2013
Tumours of the adrenal glands are very rare and information in the medical literature on the incidence, their management and maternal, fetal and neonatal outcomes is limited.
Phaeochromocytomas, tumours associated with Conn's Syndrome, andadrenal or pituitary tumours linked to Cushing's Syndrome produce excess steroid hormones which are associated with major pregnancy complications, including major maternal and fetal morbidity and mortality. Adrenal tumours are linked to higher rates of hypertension, diabetes and pre-eclampsia, as well as fetal death, intrauterine growth restriction, fetal hypoxia, fetal distress, spontaneous abortion, stillbirth and prematurity. Currently, there are no data on the incidence of adrenal tumours in pregnancy in the UK and the associated maternal, fetal and neonatal morbidity and mortality.
In addition, there are few guidelines on the appropriate pharmacological or surgical management of these tumours. Therefore, this study will examine the effects of the drugs used to treat these in relation to maternal or fetal and neonatal complications and whether the timing of the surgery to remove the tumours is important. This will allow for development of guidelines on the management of adrenal tumours in pregnancy with the ultimate aim of improving maternal and infant outcomes.
To use the UK Obstetric Surveillance System to describe the incidence, management and outcomes of adrenal tumours in pregnancy in the UK.
To use this information to develop guidelines for their optimal management.
What is the current incidence of adrenal tumours in pregnancy in the UK?
What are the outcomes for women and their babies?
How is the condition managed in the UK?
What is the role of the timing of surgery to remove the tumours and what are the complications compared to non-pregnant women in the UK?
Any pregnant women in the UK with a functioning adrenal neuroendocrine tumour, including women diagnosed pre-pregnancy who have not undergone surgery to remove the tumour.